journal article·2026-05Open access

Multi‐Organelle Stress‐Induced Paraptosis by a ROS‐Amplifying Nanocatalyst for Enhanced Cancer Immunotherapy

Zhe Yu, Haozhe Ren, Hua Li, Jinghan Zhao, Miaomiao Cao, Tian Tang, Youbei Qiao, Liting Chen, Tiehong Yang, Hong Wu

Advanced Science· Volume 13· Issue 26

Abstract

ABSTRACT Chemodynamic therapy (CDT) is severely limited by inadequate intracellular H 2 O 2 and frequent apoptosis resistance. Herein, a porous Fe 3 O 4 nanoplatform is engineered through coating of Fe 3 + ‐tannic acid complex onto nanoclusters simultaneously loaded with carbonyl cyanide 3‐chlorophenylhydrazone (CCCP, a mitochondrial uncoupler) and lactate oxidase (LOD). By self‐supplying H 2 O 2 and concurrently blocking autophagic flux, this system is engineered to potentiate CDT efficacy. Beyond the expected therapeutic outcome, we uncover that this nanoplatform triggers an unconventional cell death pathway—paraptosis. Acid‐triggered dissociation in the tumor microenvironment releases Fe 2 + /Fe 3 + for Fenton reactions while LOD simultaneously converts lactate to H 2 O 2 , overcoming the H 2 O 2 bottleneck. CCCP further synergizes this process by collapsing the mitochondrial membrane potential, which amplifies ROS leakage and culminates in an oxidative storm. This dramatic surge in ROS directly induces mitochondrial dysfunction and initiates endoplasmic reticulum stress, while also suppressing autophagic flux. Collectively, these multi‐organelle stresses markedly exacerbate intracellular damage and lead to paraptotic cell death, characterized by extensive cytoplasmic vacuolization, eliciting robust immunogenic cell death. Combined with αPD‐L1, the nanoplatform potently activates antitumor immunity and suppresses both primary and distant tumors. This work pioneers a paraptosis activation strategy driven by an iron‐based nanodrug, redefining CDT efficacy through multi‐organelle stress synergy for amplified immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Analysis School of Pharmacy The Fourth Military Medical University Xi'an China

School of Stomatology Lanzhou University Lanzhou China

State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration National Clinical Research Center for Oral Diseases Shaanxi Key Laboratory of Stomatology School of Stomatology The Fourth Military Medical University Xi'an China

State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Key Laboratory of Stomatology, School of Stomatology The Fourth Military Medical University Xi'an China

Department of Chinese Materia Medica and Natural Medicines School of Pharmacy The Fourth Military Medical University Xi'an China

Department of Radiation Oncology Xijing Hospital Air Force Medical University The Fourth Military Medical University Xi'an China

Funding

Natural Science Foundation of Shaanxi Province · National Natural Science Foundation of China

References (58)

Show source-provided references
1. 10.1038/s41573‐024‐00979‐410.1038/s41573‐024‐00979‐4 ↗
2. 10.1038/s41580‐022‐00456‐z10.1038/s41580‐022‐00456‐z ↗
3. 10.1038/s43018‐024‐00738‐910.1038/s43018‐024‐00738‐9 ↗
4. 10.1038/s41568‐021‐00435‐010.1038/s41568‐021‐00435‐0 ↗
5. 10.1002/adfm.20230094110.1002/adfm.202300941 ↗
6. 10.1002/advs.20240393510.1002/advs.202403935 ↗
7. 10.1021/acsnano.3c0136910.1021/acsnano.3c01369 ↗
8. 10.1002/adfm.20221125110.1002/adfm.202211251 ↗
9. 10.1016/j.biomaterials.2024.12270110.1016/j.biomaterials.2024.122701 ↗
10. 10.1016/j.biomaterials.2022.12168210.1016/j.biomaterials.2022.121682 ↗
11. 10.1016/j.nantod.2024.10222310.1016/j.nantod.2024.102223 ↗
12. 10.1016/j.nantod.2020.10094610.1016/j.nantod.2020.100946 ↗
13. 10.1016/j.actbio.2025.02.00810.1016/j.actbio.2025.02.008 ↗
14. 10.1016/j.cclet.2024.11077010.1016/j.cclet.2024.110770 ↗
15. 10.1038/s41401‐023‐01159‐710.1038/s41401‐023‐01159‐7 ↗
16. 10.1016/j.bcp.2023.11548710.1016/j.bcp.2023.115487 ↗
17. 10.1021/jacs.4c0778510.1021/jacs.4c07785 ↗
18. 10.1021/acsnano.4c0619910.1021/acsnano.4c06199 ↗
19. 10.1021/jacs.4c1564410.1021/jacs.4c15644 ↗
20. 10.1186/s43556‐023‐00155‐x10.1186/s43556‐023‐00155‐x ↗
21. 10.1016/j.bcp.2023.11548710.1016/j.bcp.2023.115487 ↗
22. 10.1111/bph.1738510.1111/bph.17385 ↗
23. 10.1002/adfm.20240482210.1002/adfm.202404822 ↗
24. 10.1021/acsnano.4c1145510.1021/acsnano.4c11455 ↗
25. 10.1021/acsnano.3c1017310.1021/acsnano.3c10173 ↗
26. 10.1021/acsnano.2c1196410.1021/acsnano.2c11964 ↗
27. 10.1016/j.jcis.2022.04.09010.1016/j.jcis.2022.04.090 ↗
28. 10.1016/j.jconrel.2021.06.02110.1016/j.jconrel.2021.06.021 ↗
29. 10.1021/acsnano.4c1037810.1021/acsnano.4c10378 ↗
30. 10.1016/j.biomaterials.2022.12179610.1016/j.biomaterials.2022.121796 ↗
31. 10.1016/j.bcp.2017.12.01810.1016/j.bcp.2017.12.018 ↗
32. 10.1038/s41422‐018‐0090‐y10.1038/s41422‐018‐0090‐y ↗
33. 10.1021/jacs.4c0830410.1021/jacs.4c08304 ↗
34. 10.1016/j.colsurfb.2023.11346710.1016/j.colsurfb.2023.113467 ↗
35. 10.1021/ja903300f10.1021/ja903300f ↗
36. 10.1126/scitranslmed.add271210.1126/scitranslmed.add2712 ↗
37. Dual‐Depletion of Intratumoral Lactate and ATP With Radicals Generation for Cascade Metabolic‐Chemodynamic Therapy
38. 10.1007/s12010‐022‐04003‐610.1007/s12010‐022‐04003‐6 ↗
39. 10.1016/j.cej.2023.14708410.1016/j.cej.2023.147084 ↗
40. 10.1002/smll.20200089710.1002/smll.202000897 ↗
41. 10.1126/science.116080910.1126/science.1160809 ↗
42. 10.1016/j.molcel.2022.03.02510.1016/j.molcel.2022.03.025 ↗
43. 10.1016/j.actbio.2023.02.01110.1016/j.actbio.2023.02.011 ↗
44. 10.1038/s41586‐025‐08794‐610.1038/s41586‐025‐08794‐6 ↗
45. 10.1021/acsnano.4c1145510.1021/acsnano.4c11455 ↗
46. 10.1016/j.canlet.2025.21748510.1016/j.canlet.2025.217485 ↗
47. 10.1007/978-1-4939-8885-3_2110.1007/978-1-4939-8885-3_21 ↗
48. 10.1016/j.immuni.2023.08.01410.1016/j.immuni.2023.08.014 ↗
49. 10.1016/j.cell.2023.12.01110.1016/j.cell.2023.12.011 ↗
50. 10.1002/adma.20250195310.1002/adma.202501953 ↗
51. 10.1186/s12929‐024‐01089‐410.1186/s12929‐024‐01089‐4 ↗
52. 10.1002/adma.20241507810.1002/adma.202415078 ↗
53. 10.3892/ol.2021.1288610.3892/ol.2021.12886 ↗
54. Erythroid Progenitor Cell–Mediated Spleen–Tumor Interaction Deteriorates Cancer Immunity
55. 10.1084/jem.2024044510.1084/jem.20240445 ↗
56. 10.1038/s41586‐020‐03045‐210.1038/s41586‐020‐03045‐2 ↗
57. 10.1038/s42255‐025‐01347‐110.1038/s42255‐025‐01347‐1 ↗
58. 10.1038/ni.386810.1038/ni.3868 ↗